New Insights into Adams-Oliver Syndrome Genetics

Recent breakthroughs in Adams-Oliver syndrome genetics have revealed a significant link between mutations in the valosin-containing protein (VCP) and the development of severe pulmonary hypertension (PH). Adams-Oliver syndrome (AOS) typically presents with cardinal features such as aplasia cutis congenita and terminal limb reduction defects. However, a specific subgroup of infants develops potentially lethal pulmonary hypertension. Geneticists previously struggled to explain why some patients faced this life-threatening complication while others did not. Consequently, this discovery provides a long-awaited genetic explanation for the most severe cases of the disorder.

The Pathophysiology of VCP Mutations

Research involving genome and exome sequencing has identified rare substitution variants in the VCP gene across multiple families. These AOS-related VCP variants are hypermorphic, meaning they cause overactive ATP hydrolysis. Specifically, the mutations result in hyperflexibility of the N-terminal domain, which impairs interdomain coupling within the protein. This molecular instability appears to drive the vascular abnormalities seen in affected infants. Furthermore, clinical reviews suggest that pulmonary veno-occlusive disease (PVOD) is the primary mechanism behind PH in these patients. Identifying these Adams-Oliver syndrome genetics markers allows clinicians to better predict which newborns are at the highest risk for vascular complications.

Clinical Markers and Therapeutic Potential

Clinicians should look for specific risk factors when assessing infants with AOS. Notably, cutis marmorata telangiectatica congenita (CMTC), prominent dilated subcutaneous veins, and intra-uterine growth restriction (IUGR) serve as significant red flags for pulmonary hypertension. Fortunately, the study also highlights a potential therapeutic pathway. Investigators found that CB-5083, a known VCP inhibitor, effectively inhibits overactive ATP hydrolysis in vitro. Although further clinical trials are necessary, this suggests that targeted molecular therapy could one day manage the lethal vascular symptoms associated with specific Adams-Oliver syndrome genetics.

Frequently Asked Questions

What are the primary symptoms of Adams-Oliver syndrome?

The cardinal features include aplasia cutis congenita, which is the localized absence of skin (usually on the scalp), and terminal limb reduction defects, such as missing fingers or toes. Some patients also exhibit vascular issues like pulmonary hypertension.

How do VCP mutations lead to pulmonary hypertension?

VCP mutations in AOS are hypermorphic, leading to excessive ATP hydrolysis and N-terminal domain hyperflexibility. This disruption of protein function is linked to pulmonary veno-occlusive disease, a severe form of high blood pressure in the lung vessels.

Can pulmonary hypertension in AOS be treated?

While current management focuses on supportive care, research suggests that VCP inhibitors like CB-5083 can normalize the overactive protein function in laboratory settings, offering a potential future treatment strategy.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Lehman A et al. Mutations in VCP cause Adams-Oliver syndrome with or without pulmonary hypertension. Genet Med. 2026 Apr 13. doi: undefined. PMID: 41979051.

Patel MS, et al. Abnormal pericyte recruitment as a cause for pulmonary hypertension in Adams-Oliver syndrome. Am J Med Genet A. 2004;129A(3):294-299.

Hassed S, et al. Adams-Oliver Syndrome. In: GeneReviews. University of Washington, Seattle; 1993-2024.